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ABSTRACT.
Purpose: To determine the incremental cost-effectiveness of portable electronic
vision enhancement system (p-EVES) devices compared with optical low vision aids
(LVAs), for improving near vision visual function, quality of life and well-being of
people with a visual impairment.
Methods: An AB/BA randomized crossover trial design was used. Eighty-two
participants completed the study. Participants were current users of optical LVAs
who had not tried a p-EVES device before and had a stable visual impairment. The
trial intervention was the addition of a p-EVES device to the participant’s existing
optical LVA(s) for 2 months, and the control intervention was optical LVA use only,
for 2 months. Cost-effectiveness and cost-utility analyses were conducted from a
societal perspective.
Results: The mean cost of the p-EVES intervention was £448. Carer costs were £30
(4.46 hr) less for the p-EVES intervention compared with the LVA only control. The
mean difference in total costs was £417. Bootstrapping gave an incremental cost-
effectiveness ratio (ICER) of £736 (95% CI £481 to £1525) for a 7% improvement in
near vision visual function. Cost per quality-adjusted life year (QALY) ranged from
£56 991 (lower 95%CI = £19 801) to £66 490 (lower 95%CI = £23 055). Sensitivity
analysis varying the commercial price of the p-EVES device reduced ICERs by up to
75%, with cost per QALYs falling below £30 000.
Conclusion: Portable electronic vision enhancement system (p-EVES) devices are
likely to be a cost-effective use of healthcare resources for improving near vision
visual function, but this does not translate into cost-effective improvements in quality
of life, capability or well-being.
Key words: economic evaluation – health economics – low vision aid – portable electronic vision
enhancement system – visual impairment
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Introduction
One of the major issues faced by people
with visual impairment (VI) is the
inability to perform simple tasks such
as reading and writing. In the United
Kingdom (UK), National Health Ser-
vice (NHS) low vision clinics assess the
needs of people with VI and provide low
vision aids (LVAs), such as optical
magnifiers, as a means to relieve some
of the difficulties in performing everyday
tasks. Due to the simple nature of these
devices, patients often require a variety
of aids for different tasks. There is
evidence that some optical LVAs are
never used due to the limitations of these
devices (McIlwaine et al. 1991).
In recent times, electronic alterna-
tives to optical magnifiers have become
more readily available as prices of elec-
tronic equipment have fallen. Portable
electronic vision enhancement systems
(p-EVES) are becoming a relatively
inexpensive way for people with VI to
enhance their ability to complete simple
tasks without additional assistance (see
Fig. 1 for an example of a p-EVES
device). The additional benefits of p-
EVES systems over traditional optical
magnifiers include binocular viewing,
habitual working distance, variable
magnification, adjustable contrast set-
tings and freeze frame facility (Taylor
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et al. 2014). In the Welsh NHS low
vision service, p-EVES devices are now
provided to eligible patients and anec-
dotal evidence suggests that they are
both popular and successful (Charlton
et al. 2011). However, at present p-
EVES devices are not routinely pro-
vided by NHS low vision services
throughout the rest of the UK.
The hypothesis is that in comparison
with optical LVAs, the p-EVES devices
are less tiring to use and thus can be
used for a longer duration and that
they are more versatile so can be used
for a wider range of tasks. If this is the
case, the user will experience greater
independence and is likely to rate their
health-related quality of life (HRQoL)
and well-being more highly. Previous
research has shown only limited evi-
dence that non-portable EVES devices
are more effective than optical LVAs at
improving performance of everyday
tasks (Peterson et al. 2003; Culham
et al. 2004), and to date, there has been
no published evidence regarding the
effectiveness and cost-effectiveness of
p-EVES devices.
Visual impairment (VI) is known to
be one of the leading causes of depres-
sion in older people; 13% of people
with VI have significant depressive
symptoms (Evans et al. 2007), 75% of
whom are not currently receiving treat-
ment (Nollett et al. 2016). Services and
adaptations to help people with VI
could potentially be an effective and
cost-effective means of improving the
independence, mental health and qual-
ity of life of people with untreatable VI.
Our aim was to firstly determine the
incremental cost-effectiveness of use of
a p-EVES device plus optical LVA
compared with optical LVA use alone
(using ‘near vision’ visual function as the
measure of effect). Secondly, we aimed
to estimate the cost per quality-adjusted
life year (QALY) gained fromuse of a p-
EVES device plus optical LVA com-
pared with optical LVA use alone.
Patients and Methods
Design
The p-EVES study was a single-centre
two-arm randomized crossover study
designed to determine the acceptability,
effectiveness and cost-effectiveness of p-
EVES devices as compared to optical
LVAs for ‘near vision’ tasks in adults
with moderate to severe visual impair-
ment. In this paper, we report on cost-
effectiveness; full effectiveness results
will be reported in a separate paper
which is currently under review (Taylor
J, Bambrick R, Brand A, Bray N,
Dutton M, Harper RA, Hoare Z, Ryan
B, Edwards RT, Waterman H, Dick-
inson CM; unpublished data), and a
qualitative paper reporting acceptabil-
ity is currently being prepared. The p-
EVES study was conducted at Manch-
ester Royal Eye Hospital, UK. A pub-
lished study protocol describes the study
design and methodology in detail
(Taylor et al. 2014). The p-EVES study
was registered with clinical trials.gov
(Identifier: NCT01701700), received
favourable National Research Ethics
Service (NRES) ethical approval and
conformed to the tenets of the Declara-
tion of Helsinki. Written informed con-
sent was obtained from all participants.
Study population
The trial was carried out between 2013
and 2015 in Manchester, UK. Partici-
pants were recruited through optome-
trist led low vision clinics at the
Manchester Royal Eye Hospital.
Patients were considered eligible to par-
ticipate if they were aged 18 or over, had
a visual impairment secondary to a
stable ocular pathology, had binocular
distance visual acuity of 0.7 or worse
and/or log contrast sensitivity of 1.20 or
worse and were currently in possession
of at least one near vision optical LVA.
A total of 780 patients from low vision
clinics at Manchester Royal Eye Hospi-
tal were assessed, 680 were excluded and
100 randomized. Of the 680 excluded,
533 did not meet the inclusion criteria,
117 declined, 27 could not be contacted,
and in three cases, the recruitment forms
completed by referring clinicians were
illegible.
Intervention
An AB/BA crossover trial design was
used. Participants were randomly allo-
cated to one of two possible study
arms: Group 1 or Group 2. Group 1
received the two interventions A and B
in the order AB, while Group 2
received the interventions in the order
BA. Intervention A was a 2-month
period using optical LVAs and a p-
EVES device. Intervention B was a 2-
month control period using optical
LVAs only. During intervention A,
optical LVAs were retained: they could
be used for tasks for which the p-EVES
was not suitable, or instead of the p-
EVES if preferred. Additional infor-
mation is provided in the previously
published protocol (Taylor et al. 2014).
Participants selected one of four pos-
sible p-EVESdevices depending on their
needs: theOptelecCompact4HD(£545),
the Optelec Compact+ (£249), the Sch-
weizer eMag 43 (£399) and the Eschen-
bach Mobilux Digital (£399). As per
current NHS practice, participants were
Fig. 1. Left: The Optelec Compact + which was one of the portable electronic vision enhancement
systems (p-EVES) models used in the study, set at minimum magnification. Right: The
Eschenbach 59 illuminated fixed-focus stand magnifier, which was one of the most common
optical low vision aids (LVAs) used by study participants. There is reflection of room lighting
from the lens surface, and image distortion; these would be less noticeable if used with a close eye-
to-magnifier distance, which would also increase field of view.
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not given extended formal training on
how to use the p-EVES devices beyond
basic operational demonstration.
Intervention adherence
Adherence was considered in two ways:
firstly, did the participants engage with
the purpose of the study and try to use
the p-EVES to carry out a range of tasks,
and, secondly, did participants find the
p-EVES useful enough to persist with it.
Regarding the first point, participants in
each arm of the study were phoned after
1 week to ask about any difficulties in
using the devices, and to arrange re-
instruction if required. For each partic-
ipant, the Manchester Low Vision
Questionnaire (MLVQ) was used to
record the frequency of use of aids; the
type/number of tasks completed using
each aid; the longest duration of use of
each aid; and the type/number of tasks
that could not be completed using each
aid (or which required additional assis-
tance).
Measurement of effectiveness
Two primary measures of effectiveness
were used: near vision visual function, as
measured using the NV-VFQ-15 (Stel-
mack & Massof 2007), for the cost-
effectiveness analysis; and vision-related
quality of life, as measured using the
VisQoL (Misajon et al. 2005), for cost-
utility analysis. The EQ-5D-5L (Herd-
man et al. 2011), ICECAP-A (Al-Janabi
et al. 2012) and WHO-5 (Bonsignore
et al. 2001) were used as part of sensi-
tivity analyses to examine the effect of
different measures on results.
Outcome measures
The NV-VFQ-15 is a 15-item ‘near
vision’ visual function outcome mea-
sure which was developed for this study
from the ‘near vision’ items on the NV-
VFQ-48 (Stelmack & Massof 2007). A
validated algorithm for scoring vision
function questionnaires was used to
score the NV-VFQ-15 (Massof 2007).
This scoring approximates a Rasch
analysis. Using this scoring system,
the lowest possible ‘near vision’ visual
function score on the NV-VFQ-15 is
3.36 logits, and the highest possible
score is 5.07 logits, therefore resulting
in a total score scale out of 8.43 logits.
The VisQoL is specifically designed
to measure vision-related quality of life
(Misajon et al. 2005) and is one of the
first outcome measures to allow utility
values and QALYs to be calculated for
the purpose of economic evaluation in
vision-related interventions (Peacock
et al. 2008). It is scored from 0 (state
of death) to 1 (perfect health).
The EQ-5D is a generic, validated
HRQoL measure (EuroQoL Group
1990). We used the five-level (5L) ver-
sion of the EQ-5D as this is considered
to be more sensitive than the original
three-level (3L) version (Janssen et al.
2013). At the time of analysis, a vali-
dated UK value set was not available to
score the EQ-5D-5L, and therefore, a
crosswalk value set was used to assign
weights for domain levels based on the
3L scoring system (van Hout et al.
2012). The EQ-5D-5L was analysed to
produce an index score between 0 (state
of death) and 1 (perfect health).
The ICECAP-A is a validated capa-
bility measure focussing on well-being
beyond health and is scored from 0 (no
capability) to 1 (full capability) (Al-
Janabi et al. 2012). The WHO-5 is a
validated emotional well-being index,
which is highly sensitive for screening
depressive symptoms (Lowe et al.
2004). A total score out of 100 is
calculated from the raw score.
Measurement of costs
Costing the intervention
Costs for the p-EVES devices ranged
from £249 to £545 per device. Addi-
tional staff time in low vision clinics for
demonstration of the devices was col-
lected and costed. Salary costs were
estimatedusing publishedNHSbanding
data for 2014/2015 (Royal College of
Nursing 2014). With an applied over-
head rate of 60.7% (Curtis 2011), per
hour p-EVES device demonstration
costs equated to £24.52.
Costing carer time
See Table 1 for a breakdown of carer
tasks, time codes and costs. Costs were
calculated for change in carer time
elicited by the availability of the p-EVES
aid as compared to access to optical
LVAs only. Due to the crossover design,
this was measured as change from base-
line (Visit 1) to Visit 2 for Group 1, and
change from Visit 2 to Visit 3 for Group
2, asGroup 2 essentially had a staggered
baseline due to the ‘BA’ order of inter-
ventions. The results are reported as
carer time freed up through use of p-
EVES. Carer time was costed at an
hourly rate of £6.80 (Curtis 2014).
Need for task assistance was mea-
sured using the MLVQ, which asks
respondents to estimate how often they
require assistance from another person
on 21 different tasks ranging from read-
ing small print to writing letters. Partic-
ipants were also asked to estimate daily/
weekly frequency and length of time
taken for the MLVQ tasks, but partic-
ipants reported issues in making these
estimates. In order to maintain unifor-
mity in the analysis, we consulted with a
person with over 40 years’ experience of
living with a VI to aid in assigning time
codes and estimating daily/weekly fre-
quencies for each task on the MLVQ.
Analysis of effects and costs
Twelve participants with no follow-up
data and six participants with only 2-
month follow-up data were excluded
from the analyses. Therefore, a total of
82 of 100 randomized participants were
included in the economic analyses. A
total of 38 participants were random-
ized to Group 1 and 44 to Group 2.
CROS t-tests were used to account
for participant, period and treatment
factors. The results indicated that there
was not a statistically significant effect
of moving from intervention A to
intervention B (or vice versa) on any
of the economic evaluation measures,
and therefore, the data for the two
interventions could be grouped by
intervention (A or B) across the two
study groups, allowing us to expand
the sample size to include participants
as their own comparators.
Carer time costs were collated for
both groups and compared between the
intervention A and intervention B
time-points. Mean differences in costs
between the two interventions were
calculated using nonparametric boot-
strapping, and run on 5000 iterations,
to produce 95% confidence intervals
around these differences (Briggs et al.
1997). Discounting was not undertaken
as the length of interventions did not
exceed 12 months.
Primary cost-effectiveness analysis
All economic analyses were conducted
from a societal perspective to take
account of the financial burden of carer
time. All costs are in £ sterling for 2014.
The primary cost-effectiveness analysis
e417
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compared change in ‘near vision’ visual
function, as measured using the NV-
VFQ-15, with carer and intervention
costs for the two interventions. Due to
the crossover design, effectiveness of
the p-EVES devices was measured as
change from baseline (Visit 1) to Visit 2
for Group 1, and change from Visit 2
to Visit 3 for Group 2. Effectiveness of
the optical LVA intervention was mea-
sured as change from Visit 1 to Visit 3
for Group 1, and change from Visit 1
to Visit 2 for Group 2 to account for
the different order of interventions in
the two study groups.
An incremental cost-effectiveness
ratio (ICER) was estimated using the
NV-VFQ-15 as the measure of effect.
Bootstrapping,basedon5000 iterations,
was used to generate 95% confidence
intervals aroundtheICERestimates.An
ICER plane was generated to show the
distribution of costs and effects, and a
cost-effectiveness acceptability curve
(CEAC) was generated to show the
probability of cost-effectiveness at a
specified threshold of £1000 per point
improvement on the NV-VFQ-15.
Primary cost-utility analysis
The QALY is a well-established out-
come measure in health economics
which is used to aggregate the quantity
and quality of life experienced in a given
health state. In the UK, the National
Institute forHealth andCare Excellence
(NICE) specifically endorses the QALY
as a primary outcome measure in eco-
nomic evaluations (NICE 2013). Previ-
ous research has indicated that generic
measures such as the EQ-5D are not
sensitive toqualityof life changes related
to vision and visual function (Tosh et al.
2012).TheVisQoLwas thereforeusedas
the primary outcome measure to gener-
ate a cost per QALY, ICER plane and
CEAC for comparison with the NICE
ceiling of £20 000 to £30 000 per QALY
in the UK (NICE 2013).
Area under the curve (AUC) calcula-
tions were used to estimate the overall
utility experienced during the different
intervention periods, and therefore
ICER calculations were based on differ-
ence in utility experienced during each 2-
month intervention period.
In order to calculate AUC, a base-
line score is required; however, due to
the crossover design, participants in
Group 1 received the p-EVES inter-
vention before the optical LVA only
control. This meant that calculating
AUC for the optical LVA intervention
was not possible for Group 1 without
introducing bias due to prior experi-
ence with a p-EVES device. Therefore,
optical LVA AUC data was only used
from Group 2. This resulted in a
sample size of N = 82 in the p-EVES
plus optical LVA intervention arm and
N = 44 in the optical LVA only arm.
Sensitivity analysis: outcome measures
Using the bootstrapping methods
detailed earlier, probabilistic sensitivity
analysiswasconducted togenerate ICER
planes illustrating variation in cost-effec-
tiveness from varying basic assumptions
about effectiveness and costs.
Deterministic sensitivity analysis
was conducted by altering the effective-
ness results and costs of the interven-
tion; secondary cost-effectiveness, cost-
utility and cost-capability analyses
were carried out to examine the effect
of different outcome measures on the
economic evaluation results. In the
cost-effectiveness sensitivity analysis,
the WHO-5 was used as an alternative
measure of effectiveness due to the high
incidence of depression in this popula-
tion (Evans et al. 2007). In the cost-
utility sensitivity analysis, the EQ-5D-
5L was used as an alternative measure
of utility. Additionally, the ICECAP-A
was used to calculate an estimated cost
per year of full capability (YFC); the
YFC approach is an alternative to the
QALY framework which focuses on a
broader measurement of well-being
beyond health and physical functioning
(Mitchell et al. 2015).
Sensitivity analysis: intervention costs
Three adjusted intervention cost sensitiv-
ity analyses were undertaken. In the first
sensitivityanalysis, thehighestcostdevice
(£545) was applied to all participants
alongside a standardizedhourof training
(£24.52); in the second, the lowest cost
device was applied to all participants
(£249) with no training costs; and in the
third, a real-worldWelshNHSlowvision
servicep-EVEScost(£150)wasappliedto
all participants (at the timeof this trial the
Table 1. Costing carer time: MLVQ near vision tasks and assumptions applied to unit costs.
MLVQ near vision task
Estimated time
(minutes)
Estimated
carer cost (£)*
Estimated
frequency if
not stated
Reading letters/cards/other correspondence 15 £1.70 Daily
Reading instructions (packets,
tins, bottles, medicines, etc.)
15 £1.70 Daily
Reading ‘ordinary’ print books/
newspapers/magazines
30 £3.40 Daily
Reading telephone directory to check numbers 5 £0.57 Weekly
Reading markings on dial (cooker,
radio/hi-fi, washer, etc.)
5 £0.57 Daily
Reading shop prices/labels 60 £6.80 Twice weekly
Read the time on your watch 5 £0.57 Daily
Reading large print books/newspapers 30 £3.40 Daily
Identifying money 5 £0.57 Daily
Writing own letters, cards, etc. 30 £3.40 Weekly
Signing your own name 5 £0.57 Twice weekly
Reading own writing 15 £1.70 Weekly
Filling in cheques, forms, etc. 30 £3.40 Weekly
Special hobby (e.g. stamps, models,
painting, music)
30 £3.40 Weekly
DIY/repair/fixing task 30 £3.40 Weekly
Sewing/knitting/needlework/mending 30 £3.40 Weekly
Watching TV 15 £1.70 Daily
Reading street signs/bus numbers/
directions etc.
5 £0.57 Twice weekly
Watching an event/trip/theatre 180† £20.40 Monthly
Mobile phone 15 £1.70 Daily
Looking at photographs 15 £1.70 Daily
Other NA NA NA
* Based on gross hourly salary of £6.80 for public and independent sector care worker (Curtis 2014).
† Includes travel and activity time for carer, as carer would need to be present throughout.
MLVQ = Manchester Low Vision Questionnaire, DIY = do it yourself.
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WelshserviceusedtheCompact+, not the
£150 low-cost device).
Results
Demographics
Demographic characteristics of the
sample are presented in Table 2.
Effectiveness
The mean difference in effect between
the p-EVES plus optical LVA inter-
vention and optical LVA only inter-
vention equated to a visual ability
improvement of 0.567 [95% confi-
dence interval (CI) 0.279 to 0.847]
on the NV-VFQ-15; QALY gains of
0.006 (95% CI 0.007 to 0.019) and
0.007 (95% CI 0.007 to 0.021) on
the VisQoL and EQ-5D-5L, respec-
tively; well-being improvement of
0.292 (5.073 to 5.561) on the
WHO-5; and YFC gains of 0.007
(95% CI 0.004 to 0.016) on the
ICECAP-A. The CROS t-tests
revealed a significant treatment effect
for the NV-VFQ-15 [p < 0.001,
ES = 0.57 (CI 0.33, 0.81)] and Vis-
QoL [p = 0.04, ES = 0.01 (CI 0.02,
0.05)], but not the WHO-5 [p = 0.884,
ES = 0.32 (CI 4.08, 4.72)], EQ-5D-
5L [p = 0.09, ES = 0.03 (CI 0.01,
0.07)] or ICECAP-A [p = 0.523,
ES = 0.01 (CI 0.02, 0.03)].
The statistical findings therefore indi-
cate that the intervention including p-
EVES was effective at improving ‘near
vision’ visual function and providing
additional QALYs (measured using a
vision-specific measure) as compared to
optical LVAs.
Costs
Device costs
Of the 82 participants included in the
economic analyses, 28 received a p-
EVES device costing £545, 50 received
a p-EVES device costing £399 and four
received a p-EVES device costing £249.
The average cost of a p-EVES device
was £441.54 (SD £81.53). The analysis
was focussed on the incremental costs
and benefits of p-EVES; therefore, it
was not necessary to cost pre-existing
optical LVAs which participants
already had available.
Optometrist time costs
Additional staff time required to
demonstrate how to use the p-EVES
devices ranged from five to 30 min,
with an average of 15 min (SD 6). On
average, this equated to an additional
staff time cost of £5.98 (SD £2.40) per
participant. Combined with the p-
EVES device costs, the average cost
of the p-EVES plus optical LVA inter-
vention was £447.52 (SD £82.29).
Carer time costs
During the 2-monthp-EVESplus optical
LVA intervention period (intervention
A), average carer time amounted to
29.28 hr, an opportunity cost of £199.07
(SD£155.44) tothecarer(s).Duringthe2-
month optical LVA only control period
(intervention B), average carer time
amounted to 33.74 hr, an opportunity
cost of £229.40 (SD £150.89) to the carer
(s).Themeandifference incarercostswas
therefore£30.33 (4.46 hr) with a boot-
strapped 95% CI of £76.10 to £15.99,
equating to a reducedmonthly carer cost
of £15.17 per participant.
Total costs
Factoring in the intervention device
costs, staff time and carer time costs, a
mean difference of £417.19 was found
between interventions A and B (total
costs of £646.59 and £229.40, respec-
tively), with a bootstrapped 95% CI of
£366.04 and £465.89. For the cost-
utility analysis, the mean difference in
total costs was slightly lower at £398.95
(CI £336.69 to £460.15) due to higher
mean total costs for the optical LVA
subsample (N = 42; £247.64).
Primary cost-effectiveness analysis
In total, 164 sets of data were included
in the cost-effectiveness analyses; 82
participants in both intervention arms,
as the crossover design allowed partic-
ipants to act as their own comparators.
See Table 3 for a breakdown of effec-
tiveness and ICER results. The mean
difference in total costs between the p-
EVES plus optical LVA intervention
arm and the optical LVA only arm
(£417.19, CI £366.04 to £465.89) was
divided by the mean effect (0.567 NV-
VFQ-15 points), producing an esti-
mated ICER of £735.77 (CI £481.03
to £1525.18) per unit change in ‘near
vision’ visual function.
Figure 2A shows the ICER plane
with 5000 points (100%) in the north-
east quadrant, where the intervention is
more costly but more effective. Fig-
ure 2B presents the corresponding
CEAC, which shows the probability
of cost-effectiveness at a range of
thresholds. At a cost of £481.03, the
intervention has a 2.5% probability of
Table 2. Demographic and visual characteristics of participants recruited to the study.
Group 1 (N = 49) Group 2 (N = 51)
Age (years) mean (SD) 69.79 (19.97) 72.94 (16.63)
Gender Male n (%) 20 (40.8) 18 (35.3)
Ethnicity n (%)
White British 45 (91.8) 48 (94.1)
Other 4 (8.2) 3 (5.9)
Registration (CVI) status n (%)
SSI 22 (44.9) 21 (41.2)
SI 18 (36.7) 25 (49.0)
Not registered 9 (18.4) 5 (9.8)
Residential status n (%)
Alone 19 (38.8) 24 (47.1)
With spouse/partner 11 (22.4) 10 (19.6)
With family/friends 19 (38.8) 17 (33.3)
Employment status n (%)
Employed 4 (8.2) 3 (5.9)
Unemployed 6 (12.2) 7 (13.7)
Retired 38 (77.6) 41 (80.4)
FTE 1 (2.0) 0 (0)
Binocular distance VA (logMAR) mean (SD) 0.95 (0.30) 0.96 (0.25)
Near VA (M units) at 25 cm mean (SD) 2.66 (1.67) 2.53 (1.32)
Central visual field status (CCVFT grade) mean (SD) 2.45 (1.42) 3.10 (1.54)
(Log) Contrast sensitivity (Pelli Robson) mean (SD) 0.78 (0.37) 0.75 (0.31)
CCVFT = California Central Visual Field Test, CVI = Certificate of visual impairment,
FTE = full-time education, SD = standard deviation, SI = sight impaired, SSI = severely sight
impaired, VA = visual acuity.
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cost-effectiveness; at £1525.18, there is
a 97.5% probability of cost-effective-
ness. The ICER estimate falls between
the confidence limits with a cost-effec-
tiveness probability of 48% at a cost of
£735.77 per unit change. At a threshold
of £1000 per point improvement, the
NV-VFQ-15 results demonstrate an
84.4% probability of cost-effectiveness.
Primary cost-utility analysis
A total of 82 participants were included
in the p-EVES plus optical LVA arm
and 44 in the optical LVA only control
arm (due to issues with AUC caused by
the crossover design). See Table 3 for a
breakdown of effectiveness and ICER
results. Effectiveness was expressed as
the difference in mean QALYs experi-
enced between the two interventions
over a 2-month follow-up period, which
equated to 0.006 years or 2.19 days
using the VisQoL as the primary mea-
sure of utility. Mean difference in total
costs (£398.95, CI £336.69 to £460.15)
was divided by the mean difference in
effect between the two interventions
(0.006, CI 0.009 to 0.019), yielding an
estimated cost per QALY of £66 490:
over double the upper NICE cost
threshold of £30 000 per QALY. Using
the VisQoL, 19% of the bootstrapped
estimates fell in the north-west quad-
rant, where the intervention is more
costly and less effective (see Fig. 2C).
Therefore, because the CEAC did not
exceed 81% maximum probability of
cost-effectiveness, upper confidence lim-
its could not be calculated. A one-sided
95% lower confidence limit was calcu-
lated at £23 055. Figure 2D presents the
corresponding CEAC for the VisQoL.
At a threshold of £30 000 per QALY,
there is a 14% probability of cost-
effectiveness using the VisQoL as the
measure of effect.
Sensitivity analysis: secondary cost-
effectiveness analysis
A secondary cost-effectiveness analysis
was conducted using well-being (mea-
sured using the WHO-5) as the measure
of effect. See Table 3 for effectiveness
and ICER results. Mean effect on the
WHO-5 was calculated at 0.292 (95%
CI 5.073 to 5.561), producing an
ICER of £1428.70 (one-tailed lower
95% CI 89.27) per unit change in well-
being. In total, 2329 (46.6%) of the
bootstrapped estimates fell in the north-T
a
b
le
3
.
E
co
n
o
m
ic
a
n
a
ly
si
s:
In
cr
em
en
ta
l
co
st
s
(£
)
a
n
d
o
u
tc
o
m
es
o
f
p
-E
V
E
S
d
ev
ic
e
p
lu
s
o
p
ti
ca
l
L
V
A
a
s
co
m
p
a
re
d
to
o
p
ti
ca
l
L
V
A
a
lo
n
e.
T
ri
a
l
o
u
tc
o
m
es
E
ff
ec
ti
ve
n
es
s
In
cr
em
en
ta
l
eff
ec
ti
ve
n
es
s
IC
E
R
P
ro
b
a
b
il
it
y
o
f
co
st
-e
ff
ec
ti
ve
n
es
s
B
a
se
li
n
e
m
ea
n
(S
D
)
p
-E
V
E
S
m
ea
n
(S
D
)
L
V
A
m
ea
n
(S
D
)
p
-E
V
E
S
m
ea
n
eff
ec
t
(S
D
)
L
V
A
m
ea
n
eff
ec
t
(S
D
)
E
ff
ec
t
m
ea
n
d
iff
er
en
ce
9
5
%
C
I
fo
r
m
ea
n
d
iff
er
en
ce
IC
E
R
p
o
in
t
es
ti
m
a
te
9
5
%
C
I
fo
r
IC
E
R
P
ro
b
a
b
il
it
y
a
t
th
re
sh
o
ld
IC
E
R
p
la
n
e
N
W
%
IC
E
R
p
la
n
e
N
E
%
N
V
-V
F
Q
-1
5
1
.3
7
1
(1
.2
8
)
2
.0
1
5
(1
.3
2
3
)
1
.4
4
8
(1
.2
8
4
)
0
.6
4
5
†
(1
.1
0
3
)
0
.0
7
8
(0
.7
1
4
)
0
.5
6
7
0
.2
7
9
–
0
.8
4
7
£7
3
5
.7
7
‡
, *
*
£4
8
1
.0
3
–
£1
5
2
5
.1
8
0
.8
4
0
§
§
0
(0
)
5
0
0
0
(1
0
0
)
V
is
Q
o
L
*
0
.5
5
5
(0
.2
1
8
)
0
.5
8
2
(0
.2
3
0
)
0
.5
5
3
(0
.2
2
8
)
0
.0
9
5
†
(0
.0
3
6
)
0
.0
8
9
(0
.0
3
5
)
0
.0
0
6
0
.0
0
7
–
0
.0
1
9
£6
6
,4
9
0
.0
0
§
,†
†
£2
3
,0
5
4
.5
‡
‡
0
.1
4
¶¶
9
4
9
(1
8
.9
8
)
4
0
5
1
(8
1
.0
2
)
E
Q
-5
D
–5
L
*
0
.6
2
9
(0
.2
3
2
)
0
.6
4
3
(0
.2
1
7
)
0
.6
1
1
(0
.2
4
5
)
0
.1
0
5
(0
.0
3
6
)
0
.0
9
8
(0
.0
4
0
)
0
.0
0
7
0
.0
0
7
–
0
.0
2
1
£5
6
,9
9
1
.4
3
§
,†
†
£1
9
,8
0
1
.2
‡
‡
0
.2
1
4
¶¶
8
0
3
(1
6
.0
6
)
4
1
9
7
(8
3
.9
4
)
IC
E
C
A
P
-A
*
0
.7
2
9
(0
.1
8
3
)
0
.7
5
5
(0
.1
5
3
)
0
.7
4
6
(0
.1
6
6
)
0
.1
2
5
(0
.0
2
5
)
0
.1
1
8
(0
.0
2
9
)
0
.0
0
7
0
.0
0
4
–
0
.0
1
6
£5
6
,9
9
1
.4
3
¶,
†
†
£2
6
,4
4
7
.6
‡
‡
0
.0
9
4
¶¶
5
8
9
(1
1
.7
8
)
4
4
1
1
(8
8
.2
2
)
W
H
O
-5
5
4
.6
8
3
(2
4
.2
6
2
)
5
5
.2
6
8
(2
1
.8
8
3
)
5
4
.9
7
6
(2
3
.0
7
5
)
0
.5
8
5
(1
9
.0
9
7
)
0
.2
9
3
(1
4
.7
9
1
)
0
.2
9
2
5
.0
7
3
–
5
.5
6
1
£1
,4
2
8
.7
0
‡
, *
*
£8
9
.2
7
‡
‡
0
.4
3
8
§
§
2
3
2
9
(4
6
.5
8
)
2
6
7
1
(5
3
.4
2
)
*
m
ea
n
eff
ec
t
a
n
d
IC
E
R
s
b
a
se
d
o
n
2
m
o
n
th
a
re
a
u
n
d
er
th
e
cu
rv
e
o
u
tc
o
m
es
†
si
g
n
ifi
ca
n
t
tr
ea
tm
en
t
eff
ec
t
p
<
0
.0
5
‡
co
st
p
er
p
o
in
t
im
p
ro
v
em
en
t
§
co
st
p
er
Q
A
L
Y
–
co
st
p
er
Y
F
C
*
*
ca
lc
u
la
te
d
u
si
n
g
m
ea
n
co
st
d
iff
er
en
ce
o
f
£4
1
7
.1
9
(f
u
ll
sa
m
p
le
)
†
†
ca
lc
u
la
te
d
u
si
n
g
m
ea
n
co
st
d
iff
er
en
ce
o
f
£3
9
8
.9
5
(r
ed
u
ce
d
L
V
A
co
n
tr
o
l
sa
m
p
le
d
u
e
to
A
U
C
ca
lc
u
la
ti
o
n
)
‡
‡
o
n
e-
ta
il
ed
b
o
o
ts
tr
a
p
p
ed
5
%
co
n
fi
d
en
ce
li
m
it
,
u
p
p
er
li
m
it
co
u
ld
n
o
t
b
e
ca
lc
u
la
te
d
§§
a
t
£1
0
0
0
th
re
sh
o
ld
–
–
a
t
£3
0
,0
0
0
th
re
sh
o
ld
A
b
b
re
v
ia
ti
o
n
s:
A
U
C
=
a
re
a
u
n
d
er
th
e
cu
rv
e,
C
I
=
co
n
fi
d
en
ce
in
te
rv
a
l,
IC
E
R
=
in
cr
em
en
ta
l
co
st
-e
ff
ec
ti
v
en
es
s
ra
ti
o
,
L
V
A
=
lo
w
v
is
io
n
a
id
,
N
E
=
N
o
rt
h
E
a
st
,
N
W
=
N
o
rt
h
W
es
t,
p
-E
V
E
S
=
p
o
rt
a
b
le
el
ec
tr
o
n
ic
v
is
io
n
en
h
a
n
ce
m
en
t
sy
st
em
s,
Q
A
L
Y
=
q
u
a
li
ty
-a
d
ju
st
ed
li
fe
y
ea
r,
S
D
=
st
a
n
d
a
rd
d
ev
ia
ti
o
n
,
Y
F
C
=
y
ea
r
o
f
fu
ll
ca
p
a
b
il
it
y
.
e420
Acta Ophthalmologica 2017
west quadrant, where the intervention is
more costly and less effective. At a
threshold of £1000 per point improve-
ment, the WHO-5 demonstrates a
47.8% probability of cost-effectiveness,
although it should be noted that this is
for a one-point improvement on a well-
being scale scored from 0 to 100.
Sensitivity analysis: secondary cost-utility
and cost-capability analysis
A secondary cost-utility analysis was
conducted using the EQ-5D-5L as the
measure of utility, and cost-capability
analysis using the ICECAP-A as the
measure of capability. See Table 3 for
effectiveness and ICER results. Effec-
tiveness was expressed as the difference
inmeanQALYs (EQ-5D-5L) andYFCs
(ICECAP-A) experienced between the
interventions over a 2-month follow-up
period, which equated to 0.007 years or
2.56 days on both the EQ-5D-5L and
ICECAP-A, producing a cost per
QALY/YFC of £56 991. One-sided
95% lower confidence limits were cal-
culated at £19 801 for the EQ-5D-5L
and £26 448 for ICECAP-A. At a
threshold of £30 000 per QALY/YFC
gain, probability of effectiveness was
21.4% using the EQ-5D-5L and 9.4%
using the ICECAP-A.
Sensitivity analysis: adjusted intervention
costs
Table 4 shows the sensitivity analysis
results for all adjusted intervention
costs. The higher cost sensitivity anal-
ysis (£569.52 per p-EVES intervention)
increased the mean difference in total
costs from £417.19 to £554.19 (£398.95
to £535.95 in cost-utility analysis),
increasing ICERs by between 33%
and 34%. In the lower cost sensitivity
analysis (£249 per p-EVES interven-
tion), the mean difference in total costs
decreased from £417.19 to £233.67
(£398.95 to £215.43 in cost-utility anal-
ysis), decreasing ICERs by between
46% and 48%. In the ‘real-world’
sensitivity analysis (£150 per p-EVES
intervention), the mean difference in
total costs decreased from £417.19 to
£119.67 (£398.95 to £101.43 in cost-
utility analysis), decreasing ICERs by
between 71% and 75%.
The sensitivity analyses demonstrate
that with lower device costs, p-EVES
interventions could potentially be cost-
effective according to the NICE cost
per QALY threshold of £20 000 to
£30 000; in the ‘real-world’ sensitivity
analysis, cost per QALY estimates fell
to between £14 490 and £16 905 (EQ-
5D-5L and VisQoL, respectively). It
should be noted that the ‘real-world’ p-
EVES cost of £150 is for a different
£0
£100
£200
£300
£400
£500
£600
0 0.5 1 1.5
0
0.2
0.4
0.6
0.8
1
£0 £400 £800 £1200 £1600 £2000
(a)
P
ro
ba
bi
lit
y 
in
te
rv
en
tio
n 
is
 c
os
t-e
ffe
ct
iv
e
£0
£100
£200
£300
£400
£500
£600
–0.02 –0.01 0 0.01 0.02 0.03
0
0.2
0.4
0.6
0.8
1
£0 £15 000 £30 000 £45 000 £60 000 £75 000
In
cr
em
en
ta
l c
os
t (
£)
In
cr
em
en
ta
l c
os
t (
£)
P
ro
ba
bi
lit
y 
in
te
rv
en
tio
n 
is
 c
os
t-e
ffe
ct
iv
e
(b)
(c)
(d)
(c)
Incremental effect (change on NV-VFQ-15) Cost-effectiveness threshold (£)
Incremental effect (change on VisQoL) Cost-effectiveness threshold (£)
(a)  Upper 97.5% limit for ICER
(b)  ICER ceiling threshold
(c)  ICER point estimate
(d)  Lower 2.5% limit for ICER
(e)  Lower 5% limit for ICER
(b)
(e)
ICER = Incremental cost-effectiveness ratio
(A) (B)
(C) (D)
Fig. 2. Cost-effectiveness planes (A, C) and cost-effectiveness acceptability curves (B, D) generated from cost data and NV-VFQ-15 (A, B) and
VisQoL (C, D) effectiveness data. ICER = Incremental cost-effectiveness ratio.
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device to the ones used in this study,
and therefore, the equivalence of out-
comes can only be assumed.
Discussion
Summary
The mean incremental cost, including
carer costs, of the p-EVES intervention
was £417.19. Bootstrapping gave an
ICER of £735.83 per unit change in
‘near vision’ visual function, as mea-
sured by the NV-VFQ-15. Considering
that this scale is scored from 3.36 to
5.07, the ICER point estimate relates to
a 6.7% improvement in ‘near vision’
visual function. At a threshold of £1000
per point improvement, the p-EVES
intervention had an 84.4% probability
of cost-effectiveness using the NV-
VFQ-15 as the measure of effect. Cost
per point improvement on the WHO-5
was almost 50% over the £1000 thresh-
old, which is particularly high when
considering that the scale ranges from 0
to 100.
QALY and YFC results did not show
the p-EVES intervention to be cost-
effective in comparison with optical
LVAs; however, sensitivity analyses
demonstrated that lower cost p-EVES
devices could yield better cost-effective-
ness outcomes. Overall, the results indi-
cate that p-EVES devices are a cost-
effective means of improving ‘near
vision’ visual function for people with
a VI, but this does not translate to equiv-
alent improvements in self-reported
quality of life, capability or well-being.
Current p-EVES devices supplied by
the NHS in UK cost approximately
£150, on top of the cost of any other
optical LVAs the patient may need.
This is an important consideration, as
the results indicate that p-EVES
devices could supplement optical
LVAs, not replace them. At up to five
times the cost of an optical LVA, p-
EVES devices are an additional cost to
NHS low vision services. Even if p-
EVES were to replace all currently
supplied optical LVAs, additional
funding would be needed to account
for the extra cost of p-EVES compared
with optical LVAs. The need for addi-
tional NHS funding to enable provi-
sion of p-EVES devices is therefore
apparent.
Strength and limitations
Participants were only given 2 months
with a p-EVES device. It would per-
haps have been beneficial to extend the
time-points to allow more prolonged
use of the p-EVES devices. It was
difficult to collect exact data regarding
carer time and activities using the
MLVQ as participants had difficulty
accurately recalling the frequency and
duration of assistance. In order to
counter this, we consulted with a person
with VI to develop a set of assumptions
regarding activity duration and fre-
quency. Although this is not the most
robust approach to analysing need for
assistance, it allowed us to utilize a
uniform approach to costing the data.
Due to a lack of certainty in economic
evaluations, it is common place for
health economists to apply assumptions
where robust information or data is not
available (Mogyorosy & Smith 2005).
We used probabilistic sensitivity analy-
sis, in the form of bootstrapping, to
illustrate the variation in cost-effective-
ness as a result of varying basic assump-
tions about effectiveness and costs. This
accounts for some of the uncertainty in
the data as a result of the assumptions
made in the analysis.
The analysis benefited from the
incorporation of both a generic and
disease-specific measure of HRQoL to
allow comparisons between measures.
Another strength was the inclusion of
carer time costs. Loss of productivity
and the opportunity costs of informal
care are often neglected in economic
evaluations, but from a societal per-
spective these are important consider-
ations.
Comparison with other literature
To our knowledge, this paper presents
the first robust cost-effectiveness and
cost-utility analyses of p-EVES devices.
Although economic evidence is lacking
in this field of research, a number of
previous studies have compared differ-
ent types of LVAs, including electronic
devices. To date, limited evidence has
shown that non-portable EVES devices
are more effective than optical LVAs at
improving ‘near vision’ tasks such as
reading performance. Culham et al.
(2004, 2009) found that some EVES
provide better performance of ‘near
vision’ tasks, but likewise optical LVAs
were more effective for other tasks.
Peterson et al. (2003) found that in
general, EVES enabled faster reading
speeds, but optical LVAs facilitated
faster performance of item location
tasks. There is no published evidence
about the effectiveness of the most
technologically advanced p-EVES
devices available today, such as those
used in this trial.
Implications for future research
Only the NV-VFQ-15 and VisQoL
measures demonstrated a significant
treatment effect for the p-EVES
intervention. The results from the
NV-VFQ-15 suggest that the p-EVES
intervention could potentially be a
cost-effective means of improving ‘near
vision’ visual function. However, the
results from the preference-based util-
ity and capability measures (VisQoL,
EQ-5D-5L and ICECAP-A) show that
the p-EVES intervention could not be
proven to be a cost-effective approach
to improving health status or well-
being, therefore indicating that
improvement to ‘near vision’ visual
function does not drastically affect
overall health status, or that standard
measures of health and well-being are
Table 4. Sensitivity analysis: adjusted intervention costs results.
Base case ICER
Lower intervention
cost ICER*
Higher intervention
cost ICER†
Welsh NHS
intervention
cost ICER‡
NV-VFQ-15 £735.77 £379.95 £977.41 £211.06
VisQoL £56 991.43 £35 905.34 £89 325.34 £16 904.79
EQ-5D £66 490.00 £30 776.01 £76 564.58 £14 489.82
ICECAP £56 991.43 £30 776.01 £76 564.58 £14 489.82
WHO £1428.70 £737.78 £1897.92 409.82
* All device costs reduced to £249, no optometrist time costs.
† All device costs increased to £545, 1 hr optometrist time (£24.52) for all participants.
‡ All device costs reduced to £150, no optometrist time costs.
ICER = incremental cost-effectiveness ratio.
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not sufficiently sensitive to measure
change in this population.
Previous literature shows that the
EQ-5D measures can be insensitive to
utilitychangecausedbyvisionandvisual
function (Bozzani et al. 2012; Long-
worth et al. 2014). In order to examine
the appropriateness of vision-related
and generic measures of utility in this
setting, theVisQoLandEQ-5D-5Lwere
compared in the cost-utility analyses.
The VisQoL was designed to be
sensitive to vision-related quality of life
and is an appropriate means of rapidly
estimating utility for the purpose of
economic evaluation (Peacock et al.
2008). It is therefore interesting that
both the VisQoL and EQ-5D-5L exhib-
ited relatively similar results in terms of
incremental utility gains between the
intervention arms (VisQoL = 0.006;
EQ-5D-5L = 0.007). The EQ-5D-5L
showed greater overall utility esti-
mates and a lower cost per QALY
estimate.
If we consider the VisQoL to be
more sensitive in this population, these
results would suggest that the EQ-5D-
5L was in fact overestimating utility in
this population, but both are insensi-
tive in picking up utility gains from
ability to perform normal tasks. This is
an important consideration for future
research within this field, as accurate
utility measurement is paramount in
the calculation of QALYs. Further-
more, only the VisQoL showed a sig-
nificant difference between the
intervention arms. Considering these
points, the VisQoL appears to be the
most appropriate measure of utility in
this setting.
Using the NV-VFQ-15, a 0.567 or
6.7% improvement in visual function
was found after the p-EVES interven-
tion. Equivalently sized changes to
utility and capability were not found
using any of the measures. It is first
important to reiterate that each time-
point in the study was only 2 months
long, and therefore, there may have
been insufficient time for the p-EVES
intervention to facilitate change to
broader aspects of health and well-
being. Furthermore, the NV-VFQ-15
only measures change in terms of ‘near
vision’ visual function. Quality of life,
well-being and capability are affected
by a large array of factors, and there-
fore, we would not expect to see
equivalent increases to utility as visual
function.
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